Back to Search
Start Over
Supplemental Table 1 from A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplemental Table 1. Treatment-emergent AEs (safety population)
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....071bb0c0accd07d3d7702ce3c4eeb15c
- Full Text :
- https://doi.org/10.1158/1078-0432.22461653